Partnerships

Strengthen our collaborations and develop new partner relationships to deliver life-saving innovative vaccines and therapeutic.

AT RESEARCH & DEVELOPMENT LEVEL

In order to increase the number of proofs of concept in as many diseases as possible, we have set up a multi-purpose R&D platform for therapeutic and preventive vaccine candidates against cancers, chronic and emerging infectious diseases.

The partnership with the Pasteur Institute is historically very strong, as the technology comes from the Pasteur Institute and we are licensed for patents filed by the Pasteur Institute in the field of lentiviral vectors for prophylactic and therapeutic vaccine applications for humans and animals. Beyond this partnership, our goal is to increase our partnerships, both in terms of lentiviral vector production and clinical trials and commercialisation.

OUR BUSINESS MODEL

TheraVectys aims to bring together the best skills and partners to optimize its vaccine candidates and ensure that value is created at every stage of development (R&D, technology transfer, lentiviral vectors production, clinical trials).